These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 37609317)

  • 21. Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different
    Pioner JM; Vitale G; Gentile F; Scellini B; Piroddi N; Cerbai E; Olivotto I; Tardiff J; Coppini R; Tesi C; Poggesi C; Ferrantini C
    Front Physiol; 2022; 13():864547. PubMed ID: 35514357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy.
    Ahmad F; Banerjee SK; Lage ML; Huang XN; Smith SH; Saba S; Rager J; Conner DA; Janczewski AM; Tobita K; Tinney JP; Moskowitz IP; Perez-Atayde AR; Keller BB; Mathier MA; Shroff SG; Seidman CE; Seidman JG
    PLoS One; 2008 Jul; 3(7):e2642. PubMed ID: 18612386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments.
    Robinson P; Griffiths PJ; Watkins H; Redwood CS
    Circ Res; 2007 Dec; 101(12):1266-73. PubMed ID: 17932326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variant R94C in
    Ezekian JE; Clippinger SR; Garcia JM; Yang Q; Denfield S; Jeewa A; Dreyer WJ; Zou W; Fan Y; Allen HD; Kim JJ; Greenberg MJ; Landstrom AP
    J Am Heart Assoc; 2020 Mar; 9(5):e015111. PubMed ID: 32098556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
    Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
    J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel nonsense mutation in TNNT2 in a Chinese pedigree with hypertrophic cardiomyopathy: A case report.
    Gao G; Liu G; Chen W; Tong Y; Mao C; Liu J; Zhang X; He MM; Yang P
    Medicine (Baltimore); 2020 Aug; 99(34):e21843. PubMed ID: 32846832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human induced pluripotent stem cell line YCMi007-A generated from a dilated cardiomyopathy patient with a heterozygous dominant c.613C > T (p. Arg205Trp) variant of the TNNT2 gene.
    Jeon SB; Kim H; Chun KH; Oh J; Kwon C; Choi HK; Kim S; Kim HP; Kim IC; Yoo JY; Park SW; Kang SM; Lee SH
    Stem Cell Res; 2023 Mar; 67():103048. PubMed ID: 36801602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac troponin T is essential in sarcomere assembly and cardiac contractility.
    Sehnert AJ; Huq A; Weinstein BM; Walker C; Fishman M; Stainier DY
    Nat Genet; 2002 May; 31(1):106-10. PubMed ID: 11967535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in zebrafish.
    Becker JR; Deo RC; Werdich AA; Panàkovà D; Coy S; MacRae CA
    Dis Model Mech; 2011 May; 4(3):400-10. PubMed ID: 21245263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca
    Sparrow AJ; Watkins H; Daniels MJ; Redwood C; Robinson P
    Am J Physiol Heart Circ Physiol; 2020 Mar; 318(3):H715-H722. PubMed ID: 32083971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM.
    Piroddi N; Witjas-Paalberends ER; Ferrara C; Ferrantini C; Vitale G; Scellini B; Wijnker PJM; Sequiera V; Dooijes D; Dos Remedios C; Schlossarek S; Leung MC; Messer A; Ward DG; Biggeri A; Tesi C; Carrier L; Redwood CS; Marston SB; van der Velden J; Poggesi C
    J Gen Physiol; 2019 Jan; 151(1):18-29. PubMed ID: 30578328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertrophic cardiomyopathy mutations increase myofilament Ca
    Robinson P; Liu X; Sparrow A; Patel S; Zhang YH; Casadei B; Watkins H; Redwood C
    J Biol Chem; 2018 Jul; 293(27):10487-10499. PubMed ID: 29760186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of DYRK1A Expression on TNNT2 Splicing and Daunorubicin Toxicity in Human iPSC-Derived Cardiomyocytes.
    Cejas RB; Tamaño-Blanco M; Fontecha JE; Blanco JG
    Cardiovasc Toxicol; 2022 Aug; 22(8):701-712. PubMed ID: 35596909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.
    Alves ML; Dias FAL; Gaffin RD; Simon JN; Montminy EM; Biesiadecki BJ; Hinken AC; Warren CM; Utter MS; Davis RT; Sakthivel S; Robbins J; Wieczorek DF; Solaro RJ; Wolska BM
    Circ Cardiovasc Genet; 2014 Apr; 7(2):132-143. PubMed ID: 24585742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of a truncated cardiac troponin T that causes familial hypertrophic cardiomyopathy: Ca(2+) regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein.
    Redwood C; Lohmann K; Bing W; Esposito GM; Elliott K; Abdulrazzak H; Knott A; Purcell I; Marston S; Watkins H
    Circ Res; 2000 Jun; 86(11):1146-52. PubMed ID: 10850966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vivo Analysis of Troponin C Knock-In (A8V) Mice: Evidence that TNNC1 Is a Hypertrophic Cardiomyopathy Susceptibility Gene.
    Martins AS; Parvatiyar MS; Feng HZ; Bos JM; Gonzalez-Martinez D; Vukmirovic M; Turna RS; Sanchez-Gonzalez MA; Badger CD; Zorio DAR; Singh RK; Wang Y; Jin JP; Ackerman MJ; Pinto JR
    Circ Cardiovasc Genet; 2015 Oct; 8(5):653-664. PubMed ID: 26304555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Correlation of cardiac troponin T gene mutations to hypertrophic cardiomyopathy in Chinese patients].
    Li M; Cheng K; Wang QB; Zhu WQ; Chen RZ; Ge JB; Chen HZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1589-91. PubMed ID: 21945774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
    Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
    J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy.
    Revera M; van der Merwe L; Heradien M; Goosen A; Corfield VA; Brink PA; Moolman-Smook JC
    Cardiovasc Res; 2008 Mar; 77(4):687-94. PubMed ID: 18029407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in troponin T associated with Hypertrophic Cardiomyopathy increase Ca(2+)-sensitivity and suppress the modulation of Ca(2+)-sensitivity by troponin I phosphorylation.
    Messer AE; Bayliss CR; El-Mezgueldi M; Redwood CS; Ward DG; Leung MC; Papadaki M; Dos Remedios C; Marston SB
    Arch Biochem Biophys; 2016 Jul; 601():113-20. PubMed ID: 27036851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.